CD44 and prostate carcinoma: γ-tocotrienol is also an effective agent in targeting prostate cancer stem cells through the down-regulation of stemness markers (CD133, CD44), the elimination of chemoresistance, and decreased viability (both in vitro and in vivo) [239].